Complicated Skin And Skin Structure Infections Drugs Market Size, Insights, Growth Rate, Trends Analysis And Forecast To 2033

The complicated skin and skin structure infections drugs market size has grown rapidly in recent years. It will grow from $8.55 billion in 2023 to $9.51 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to infectious disease prevalence, increase in hospital-acquired infections, prevalence of complicated skin and skin structure infections, growing demand for effective treatment options, rising disposable incomes.

The complicated skin and skin structure infections drugs market size is expected to see strong growth in the next few years. It will grow to $13.78 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing investment in r&d activities, rising demand for novel antibiotics, increasing incidence of antibiotic-resistant infections, growing demand for personalized medicine. Major trends in the forecast period include advancements in wound care products, targeted antibiotics, digital health monitoring, natural and alternative remedies, global collaborations.

Market Overview -
Complicated skin and skin structure infections (cSSSI) drugs are a type of medication treating various skin and soft tissue infections (SSTI) that affect the skin and deeper soft tissues, such as muscles, fascia and subcutaneous tissues, caused by bacterial species. Proper management of these infections is crucial to preventing complications and improving patient outcomes.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=12940&type=smp

Rising Skin Disease Prevalence Fueling Growth In Complicated Skin And Skin Structure Infections Drugs Market
The increasing prevalence of skin disease is expected to propel the growth of the complicated skin and skin structure infections drugs market going forward. Skin diseases are medical conditions that affect the skin's appearance, structure and function. These conditions can involve the skin, hair, nails and related tissues. Various antibiotic drugs are used to treat resistant bacteria in cSSSI. Thus, the rise in skin disease cases can lead to new cSSSI drug approvals, raise awareness and promote early diagnosis of complicated skin and skin structure infections. For instance, in April 2022, according to the American Academy of Dermatology Association, a US-based non-profit medical specialty association, approximately 9,500 people in the US will be diagnosed with skin cancer daily. Furthermore, in March 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, the total number of deaths from fungal infections increased from 5,922 in 2020 to 7,199 in 2021. Therefore, the increasing prevalence of skin disease drives the growth of the complicated skin and skin structure infections drugs market.

Competitive Landscape -
Major players in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd., Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, LEO Pharma, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.

Evolving Treatment Landscape To Gain A Competitive Edge
Major companies operating in the complicated skin and skin structure infections drugs market are developing innovative products, such as Xydalba, to gain a competitive edge in the market. For instance, in January 2022, Paladin Labs Inc., a Canada-based pharmaceutical company and a subsidiary of Endo International PLC, launched Xydalba (dalbavancin for injection) in Canada, an intravenous therapy that treats acute bacterial skin and skin structure infections (ABSSSI) in adults and children aged three months and older. Xydalba is a second-generation semi-synthetic lipoglycopeptide antibiotic that interferes with forming bacterial cell walls, effectively killing the bacteria. It is effective against many gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). ABSSSI (Acute Bacterial Skin and Skin Structure Infections) is a subset or a specific classification of complicated skin and skin structure infections (cSSSI).

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/complicated-skin-and-skin-structure-infections-drugs-global-market-report

Key Segments -

The complicated skin and skin structure infections drugs market covered in this report is segmented -

1) By Active Ingredients: Delafloxacin; Vancomycin; Ceftaroline Fosamil; Linezolid; Other Active Ingredients
2) By Route of Administration: Oral; Topical; Parenteral
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.